Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
Schizophrenia
About this trial
This is an interventional prevention trial for Schizophrenia focused on measuring Memantine, Negative syndrome, Schizophrenia, Cognitive impairment, Glutamate
Eligibility Criteria
Inclusion Criteria: Diagnosis of schizophrenia (DSM-IV) Age 18 to 40 Exacerbation of an acute schizophrenic episode (PANSS positive score > 20) At least one previous schizophrenic episode Informed consent Subjects must be considered by the investigator to be compliant Subjects must have an educational level and a degree of understanding such that they can meaningfully communicate with the investigator Exclusion Criteria: Axis I disorder other than schizophrenia within 12 months, e.g. schizoaffective disorder Severe negative symptomatology (PANNS negative score >20 points) Duration of schizophrenia > 5 years Dependency on alcohol or addictive drugs within 6 months of the baseline evaluation Contraindication of risperidone Significant neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests Prior ECT-treatment, metal implantations Female subjects during pregnancy and breastfeeding Female subjects within childbearing years who were not using adequate birth control Patients who are judged by the investigator to be at serious suicide risk
Sites / Locations
- Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Memantine plus Risperidone
Placebo plus Risperidone
6 weeks 20 mg Memantine as add-on treatment to Risperidone
6 weeks 20 mg Placebo as add-on treatment to Risperidone